Sotera Health Company Common Stock (SHC) fair value

ACCE thesis

Sotera Health provides sterilization services (ethylene oxide, gamma, and electron beam), along with lab testing and microbiological and biological indicator products, serving medical device and pharmaceutical customers. Its moat is practical: sterilization capacity is regulated, capital-intensive, and hard to relocate once a customer's device validation is built around a given site, which supports the 38.0% operating margin and 55.0% gross margin. Revenue growth of 9.2% sits alongside a forward P/E of 17.8 against a trailing 31.7, so earnings are expected to recover sharply from current levels, and the next test is whether that shows up in reported numbers. The stock is not in any major index, which can keep a name of this size under-followed and worth a look for a concentrated book. The trailing multiple and the gap to the forward figure are the first things to pressure-test, along with ethylene oxide regulation that could raise compliance costs at specific sites.